StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
6-factor scoring with sector-relative rank. Updated daily.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $39.57 | $39.59 | +0.05% | 1.0M |
| 05-12 | $39.59 | $39.61 | +0.05% | 1.5M |
| 05-13 | $39.61 | $39.58 | -0.08% | 1.8M |
| 05-14 | $39.60 | $39.60 | +0.00% | 1.6M |
| 05-15 | $39.60 | $39.59 | -0.03% | 0.5M |
No sell-side coverage available for CNTA.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Fundamentals not available for CNTA.
No fundamental metrics available yet for this ticker — common for ETFs, foreign issuers without US listing depth, very recent IPOs, or thinly-traded OTC names. The Financials tab pulls from SEC EDGAR directly and may still have data.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $0.00 | $15.00M | $15.00M | $15.00M |
Operating Income | $-79.77M | $-207.69M | $-139.22M | $-85.43M |
Net Income | $-79.24M | $-197.53M | $-131.37M | $-76.48M |
EPS (Diluted) | $-0.52 | $-1.46 | $-0.98 | $-0.57 |
Total Assets | $641.76M | $687.50M | $448.30M | $492.13M |
Total Liabilities | $154.41M | $160.63M | $146.73M | $147.21M |
Cash & Equivalents | $62.43M | $61.30M | $50.81M | $44.24M |
Free Cash Flow OCF − CapEx | Not available | $-194.19M | $-138.37M | $-79.82M |
Shares Outstanding | 154.73M | 149.23M | 134.42M | 133.91M |
Centessa Pharmaceuticals PLC is a clinical-stage biotechnology company pioneering a new class of therapeutics in orexin-based neuroscience. The group is developing a franchise of small molecule orexin receptor 2 (OX2R) agonists designed to address neuroscience diseases underpinned by dysregulation of wakefulness, attention, cognition, mood, and other symptoms, each grounded in the shared biology of the orexin pathway. The company's programs and Pipeline are the Orexin Receptor 2 Agonist Program and LockBody Technology Platform.
What you need to know right now
This is an algorithmic assessment of current technical conditions, not investment advice. Past performance does not guarantee future results.
CNTA is in the extended universe. We surface dollar-volume + price-change percentiles for every US-listed name, but the full 6-factor DNA breakdown (momentum, news, sentiment, flow, relative strength) is only computed on the curated 1138-name primary list.
DNA analysis is not available for this ticker.